市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Ascendis Pharma A/S | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.25 |
|
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.78% |
| 机构持股比例 | 110.29% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 280.00 (Evercore ISI Group, 62.73%) | 购买 |
| 中 | 208.50 (21.18%) | |
| 低 | 200.00 (JP Morgan, 16.24%) | 购买 |
| 200.00 (Cantor Fitzgerald, 16.24%) | 购买 | |
| 平均值 | 220.33 (28.05%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 160.16 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Evercore ISI Group | 02 May 2025 | 280.00 (62.73%) | 购买 | 172.06 |
| 18 Feb 2025 | 260.00 (51.11%) | 购买 | 156.19 | |
| Wedbush | 02 May 2025 | 212.00 (23.21%) | 购买 | 172.06 |
| RBC Capital | 16 Apr 2025 | 205.00 (19.14%) | 购买 | 158.15 |
| JP Morgan | 18 Mar 2025 | 200.00 (16.24%) | 购买 | 164.65 |
| 13 Feb 2025 | 168.00 (-2.36%) | 购买 | 142.49 | |
| Cantor Fitzgerald | 25 Feb 2025 | 200.00 (16.24%) | 购买 | 151.53 |
| 11 Feb 2025 | 170.00 (-1.20%) | 购买 | 119.51 | |
| Goldman Sachs | 13 Feb 2025 | 225.00 (30.77%) | 购买 | 142.49 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合